Xencor, Inc. (NASDAQ:XNCR) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $34.00.

A number of brokerages recently weighed in on XNCR. Bank of America raised their price target on shares of Xencor from $20.00 to $26.00 and gave the company a “neutral” rating in a report on Monday, September 21st. Wall Street Zen raised Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, September 21st. JPMorgan Chase & Co. lifted their target price on Xencor from $14.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, September 3rd. Finally, Raymond James Financial boosted their target price on Xencor from $40.00 to $46.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, September 1st.

Institutional Trading of Xencor

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XNCR. BlackRock Inc. acquired a new position in Xencor during the 2nd quarter valued at about $219,785,000. Primecap Management Co. CA bought a new position in shares of Xencor in the 2nd quarter valued at about $163,919,000. BVF Inc. IL grew its position in shares of Xencor by 160.3% during the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock worth $109,217,000 after buying an additional 4,393,579 shares during the period. Legal & General Group Plc grew its position in shares of Xencor by 2.8% during the 4th quarter. Legal & General Group Plc now owns 1,308,088 shares of the biopharmaceutical company’s stock worth $20,027,000 after buying an additional 35,088 shares during the period. Finally, Dimensional Fund Advisors LP raised its stake in shares of Xencor by 3.6% during the first quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock worth $15,613,000 after buying an additional 45,599 shares during the last quarter.

Xencor Stock Up 0.3%

Shares of NASDAQ:XNCR opened at $24.84 on Friday. The firm has a market cap of $1.85 billion, a P/E ratio of -11.45 and a beta of 0.89. Xencor has a 12 month low of $10.38 and a 12 month high of $30.61. The company’s 50-day moving average price is $24.32 and its two-hundred day moving average price is $17.09.

Xencor (NASDAQ:XNCR) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same period in the previous year, the firm posted ($0.41) earnings per share. The company’s revenue was up 17.4% on a year-over-year basis. As a group, equities analysts predict that Xencor will post -3.05 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company that develops engineered monoclonal antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious medical conditions. The company’s research is based largely on its XmAb technology platform, which is designed to modify antibody structures to improve immune-system activity, extend drug half-life or enable the simultaneous targeting of multiple biological pathways.

Xencor’s pipeline includes investigational therapies intended to engage immune cells, regulate immune responses and target tumor-associated proteins.